Amarin Corp PLC News - AMRN

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Form 4 - Statement of changes in beneficial ownership of securities

Amarin Chairman & CEO Issue Letter to Shareholders

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

-- Reported Unaudited Total Revenues of Between $72 Million - $74 Million in the Fourth Quarter of 2023...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN...

Form 4 - Statement of changes in beneficial ownership of securities

FlyFishingStocks 1 hour ago

"Stay with the program"? What's that supposed to mean? So are you saying Alex Denner (Sarissa) involvement had nothing to do with a -65% drop in the share price while the Bio index rose +65%. How is that "squirming past the facts? Do I need to remind you PRICE IS KING... PRICE IS FACT!

Quit trying to bamboozle people into thinking you know what you’re talking about?

The only person who has been bamboozled is you.

👍️0

Gusman 1 hour ago

le pain et le loueil d'olive is optional It is one of the most beautiful towns I have been in and would recommend to anyone. Very close to Spain with just the Pyrenees to cross. Nice local vin yards.

👍️0

rosemountbomber 2 hours ago

Wow that’s as close to Spain as you can get. Never been to an anchovie bar - do they have bread and butter to go with that?

Surely, they should recognize the value of EPA.

👍️0

ramfan60 2 hours ago

Can only hope they nail this guy and other like him

https://finance.yahoo.com/news/us-accuses-short-seller-andrew-125959087.html

👍️0

CaptBeer 3 hours ago

Come on France! Pull your Head Out!

👍️0

Gusman 3 hours ago

i spent the last two weeks in the south of France near Collioure and they have Bar À Anchois - Anchoive Bars - i was in heaven, white wine and Anchovies- its the EPA stupid

But on a serious matter does Amarin have to overcome the Anchovies lobby to get reimbursement approval in France? O la la...

👍️ 1 😁 1

Number sleven 6 hours ago

https://gmmmg.nhs.uk/updated-lipid-pathway/
Sleven,

👍️ 2

rosemountbomber 6 hours ago

Along with suggesting Icosapent Ethyl to those patients they should also suggest to the French govt agency in charge to hurry up with their reimbursement for Vazkepa.

But like you say, slow but sure the data is mounting, and they eventually have to succumb.

👍️ 1

ramfan60 7 hours ago

Nice find Sleven............. drip drip drip of good positive affirmation information

👍️0

Number sleven 7 hours ago

https://www.annalsofvascularsurgery.com/article/S0890-5096(23)00679-9/abstract
Sleven,

👍️ 1

ORBAPU 9 hours ago

About time. Hope others get indicted as well.

https://www.wsj.com/finance/stocks/u-s-accuses-prominent-short-seller-andrew-left-of-fraud-0161e42f

👍️ 2

CaptBeer 9 hours ago

Looks like VASCEPA®/VAZKEPA® safety profile in the Real World (RW) is significantly better than reported in the REDUCE-IT RCT & the labels in the USA & Europe. Check out these AE rate comparisons. VASCEPA®/VAZKEPA® = Safe & Effective.#IPE @SABOURETCardio @DLBHATTMD pic.twitter.com/QNelYdvOGU— Mike Everts (@GeoWizz_) July 26, 2024

👍️ 1

Nukemtiltheyglow 10 hours ago

I like how you squirm past the facts. Your question to Irish was about Alex Denner (Sarissa) involvement and who controlled Amarin’s destiny when the share price was last time @ $4.77?

So, what’s happened since then is apparently in your perspective all Alex Denner & Sarissa’s fault? Really? Stay with the program. Quit trying to bamboozle people into thinking you know what you’re talking about?

👍️ 1

north40000 10 hours ago

AMRN has traded more in line with the small-cap biotech index, not the XBI or even the Russell 2000 index. I picked AMRN as my top pick in a IHub contest of 10 savvy LT picks that began in early May and will end in late April or May 2025. My entry point for AMRN in the contest is $0.688. Other picks with entry values are CDMO= $7.14, ATNM= $7.40, AVXL= $4.22, MAGS= $45.11, MNMD= $7.21, NVDL= $69.55, NWBO= $0.428, VKTX= $53.01 and XERS= $2.25. None of those picks can be traded on a short term basis; all are LTBuyHOLD. Contestants hope that each of their picks will have a higher share price at contest end next year, with buyouts/M and A activity at multiples of entry values a possibility.

👍️ 1 💩 1

IgnoranceIsBliss 10 hours ago

I'm tastytheelf by the way. MRM made me change my handle.

👍️ 3 🤡 1

IgnoranceIsBliss 10 hours ago

If they are maintaining a $50mm buyback (we'll have to see what they say in the Q2 earnings call), and they want to do it like grown-up companies do, then they'd stretch it out over like 6 months to a year, and there would be some opportunism to it.

You'd be looking at 250k to 500k shares per trading day I would think. Right now that would distort the market and drive the price up.

👍️0

IgnoranceIsBliss 10 hours ago

It should be! It isn't some kind of Frankenstein gene-altering, cancer-causing chemical -- it's a natural extract!

👍️0

JRoon71 11 hours ago

Nice find Dogn, thank you.

Efficacy - CHECK!
MO Placebo Issue Debunked - CHECK!
AFib Risk Debunked - CHECK!

👍️ 3

CaptBeer 17 hours ago

The Absolute Risk of these two AE’s in trial vs. placebo were very low to begin with. It appears that in the RW the risk is nearly zero.

V is possibly the safest of any CV drug while delivering efficacy >= statins and cost effectiveness 3-5X than PCSK-9’s.

👍️ 3

CaptBeer 17 hours ago

Our Friend, Dr John Nelson once again brilliantly showing the consistency of REDUCE-IT data and how safe VASCEPA/VAZKEPA is in the Real World. All the negative hype about bleeding and Afib with IPE is laid to rest.

👍️ 2

ramfan60 18 hours ago

Great positive example of the V safety profile. The real world data shows far less adverse events than the Reduce-It study results.

👍️ 1

dogn 19 hours ago

Journal of Clinical Lipidology
Volume 18, Issue 4, Supplement, July–August 2024, Page e574

Comparison of Package Insert versus Real World Safety Data from Branded Icosapent Ethyl Users: A Select Analysis Utilizing MarketScan Data.

https://www.sciencedirect.com/science/article/abs/pii/S1933287424001594

Conclusions
RWD demonstrated trends in the frequency of IPE-labeled AEs that are consistent with, but 3-5x lower than, trial and labeling data. Potential reasons for consistently lower AE rates in RWD compared with trial data may be related to differences in how AEs are assessed and documented in the real world vs. in trials.

👍️ 5

FlyFishingStocks 22 hours ago

October 25, 2021 Amarin closed at 4.77. Who was running the company? Who was in the Whitehouse? Screwing with the interest rates and giving $Billions to Ukraine? We were neck deep with Covid as well. Perfect storm?

Well, if it has been such a "perfect storm," how do you answer the biotech group index rising from 62.05 to the high today of 102.11 over the past 2 years (a + 65% increase)? AMRN, on the other hand, over that same time frame eroded 64% of its share value; exactly the opposite of its index. That debunks your Whitehouse resident, CEO, Billions to Ukraine, interest rate screw job, and Covid theory.

"Get a life" man.

👍️ 1

hayward 23 hours ago

FlyFishingStocks

Still think the buy back is in progress ? Total volume today less then 400,000 shares traded TIA

Michael

👍️0

marzan 23 hours ago

FFS, should we add more, hold, or sell before the Q next Wednesday. What does the chart say? Thanks in advance.

👍️0

Nukemtiltheyglow 1 day ago

👍️0

Nukemtiltheyglow 1 day ago

I’ll answer for Irish; it’s called who resides in the Whitehouse!!! And who was at the helm 2 years ago when the stock cratered.

Jesus man get a life.

👍️0

FlyFishingStocks 1 day ago

Still waiting mr. denial for your opinion as to why/how the stock price plunged from $4.50 to .65 spanning the time of Denner's involvement to date.

Do you not have an answer?

👍️0

Jasbg 1 day ago

JR, Have to agree with you here. Denner and Sarissa 'likely have a lot of influence' on how Amarin is run - but as you said 'Denner is NOT on the board'.

And Hedge Funds works often in 'teams' - no way anyone can say that Sarissa is (not though partners) shorting Amarin - if they valuate that to be the best short term way to do business / make money.
-------------------------

And I am with you all the way - that Sarissa and Denner have 'big long term plans' for Amarin.

I like $10- 15 better than $5. BO announcement will be there some day - 2025 - 26 - not unlikely, if besides UK - a couple of other big countries in EU and possibly China - will start to create noticeable revenue ✌️

👍️0

Number sleven 1 day ago

DAR, The case I posted looks like it might be Canadian. If so, it doesn't represent a precedent we can use.
CAFC has already ruled on the appeal.
Sleven,

👍️ 1

DAR53 1 day ago

NS, thanks for the link. So based upon this case, it would appear to me that no only is Hikma infringing (case ongoing), but the other generics could be found guilty of infringement against Amarin. The skinny label is certainly be infringed upon in the CVD area regardless of the fault of doctors, insurers or PBMs. Amarin has to gain traction on some of these legal cases as precedent.
I don't recall the date for the Hikma / Amarin CAFC official response. Is that August 13?

👍️0

ramfan60 1 day ago

Lowest volume day that I can remember..... will be interesting to see what happens in the next 8 mins

👍️0

Number sleven 1 day ago

JRoon, I will find and post the actual ruling later. This infringement case is almost identical to the situation that Amarin is in. The generic companies have a mono therapy label. Our label involves combination therapy. Ths is the same situation as the case I posted. Apotex was found guilty of inducing infringement because the majority of patients being treated were given combination therapy.
Sleven,

👍️ 3

irishpaddy 1 day ago

Hey mister come afterwards
Laws are laws and board directors are well aware of where Bernie Madoff ended up...of course companies short but Sarissa Denner in this case cannot. You know zero about what I have held or not held, you of 0000's of posts on 1 stock...
Why would you only discuss one stock if you actually knew trading...with graphs handles tails of yours but only 1 stock..
We know what you are ..

👍️0

JRoon71 1 day ago

Good find, Sleven.

The last paragraph was interesting:
This case suggests that, in order to succeed in “skinny label” cases, a generic manufacturer may need to overcome established prescribing practices, which may be influenced not only by the patentee’s label but its market tenure as well.

👍️0

FlyFishingStocks 1 day ago

Hey thur mr. denial. Let's hear your opinion as to why/how the stock price plunged from $4.50 to .65 spanning the time of Denner's involvement to date. Be sure to lace it with facts (as you demand of other posters).

Based on my opinion/strategy (which I'm sure you are aware of), I am shocked you have held your shares clear down to the bottom - especially since you proclaim to be so smart. You have chosen to see the AMRN investment completely opposite to my thinking, but that's your opinion. Differing opinions are the very ingredients that make up a 'market' composed of buyers and sellers. That's why companies like Sarissa can exploit FOMO retail and become filthy wealthy.

Don't overdose on your grumpy pills.

👍️ 1

Number sleven 1 day ago

https://www.torys.com/en/our-latest-thinking/publications/2023/12/lr-2023/federal-court-of-appeal-skinny-label-case-highlights-the-potential-power-of-the-patentee
Sleven,

👍️0

JRoon71 1 day ago

Kiwi, no disclosure of buyback yet. And no filings. So "officially", no shares purchased yet. But there's still the possibility that Cantor is buying and accumulating in their own account, and have not transferred shares to Amarin yet. I imagine Amarin will need to explain where they are in the process at the CC next week.

As far as shorting, you are correct, board member cannot short. However, this does not prohibit Sarissa (the investment firm) from shorting (as they stated in their proxy) until they reach 10% ownership. It also does not prevent any "partners" from shorting.

But they would not state in their SEC filing that they could potentially short the stock, if that were illegal.

👍️ 1

Whalatane 1 day ago

RMB My quick take is that most companies prohibit members of the BOD from shorting their Co's stock ...for reasons mentioned by others here .
However there maybe loop holes that Denner / Sarissa are using to short if they wanted to....and they have disclosed as such .

What I think is more significant is has AMRN disclosed any buy back purchases yet ?
I've been on vacation so haven't followed the board much lately .
Any news on the share buyback ?
Kiwi

👍️0

JRoon71 1 day ago

Yeah, I was just commenting on the thread in general.

👍️0

irishpaddy 1 day ago

Rainy

Just go away
Soft sly bashing
Anyone connected in any way with Sarissa / Dinner would be put away for years for that.
Consistently you suggest the most idiotic unbelievably stupid ideas as if you had intellect.
To school boy now

👍️0

rosemountbomber 1 day ago

I wasn’t speaking to any of those questions or points, only trying clear up any possible confusion as to whether the 10% applied to directors - in any public company.

👍️0

Chromosome 1 day ago

Anyone on a BoD that shorts the stock of the company they are charged with as a fiduciary should be fired immediately, regardless of legality. I have never heard of anyone on a BoD do that.

👍️0

JRoon71 1 day ago

Who said anyone on the board was doing this directly?

Also, Alex Denner is not on the Board.

👍️0

irishpaddy 1 day ago

Rose

Yes exactly
BOD must declare irrespective of the size of their holdings. It would plainly be insider trading as they would have knowledge before anyone else.

👍️0

rosemountbomber 1 day ago

Kiwi, not sure if it was because I knew 3 languages before starting kindergarten, but I seemed to have a bit of difficulty with comprehension.

So maybe I am not clear on this, but the SEC rule you posted, I understand to mean that the 10% only applies to shareholders. Otherwise, executives or directors (BOD) would have to declare before shorting the way I comprehend it, right?

👍️0

Whalatane 1 day ago

Section 16 of the Securities Exchange Act of 1934:
Under Section 16, executive officers, directors, and significant shareholders (those owning more than 10% of the company's stock) must file public reports disclosing their holdings and transactions in the company's equity securities. Transactions must be reported within two business days using Form 4

Kiwi

👍️ 1

Meowza 1 day ago

Thank you for belying the bipolar egomaniacal cardiologist stereotype.

👍️0

irishpaddy 1 day ago

Ruin
Nope
Sarissa as an investment entity may short declare able shareholdings which they state in their company information. Once they take up board positions they become insiders and as such if they were to even intend to short or go long they must declare that intent in advance.
Ruiny back to school boy.

👍️0

north40000 1 day ago

Readers may want to look at/skim read a willful infringement, damages case/opinion released Tuesday this past week in the E.D Texas after entry of redactions:

NETLIST v. SAMSUNG et al

Post # 24778 on the NETLIST IHub board.

About $500,000,000 damages found by a jury. Different facts and patents of course, but note that Hikma(like Samsung) does continue to sell product after filing of Amarin complaint. Will Hatch Waxman make a difference? Reread the recent CAFC opinion in Amarin v. Hikma.

👍️ 1

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Amarin Corp PLC (AMRN)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

AMRN News

Form 4 - Statement of changes in beneficial ownership of securities

Amarin Chairman & CEO Issue Letter to Shareholders

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

AMRN Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Amarin Corp PLC (AMRN) News

Amarin Corp PLC (AMRN)

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

AMRN News

Form 4 - Statement of changes in beneficial ownership of securities

Amarin Chairman & CEO Issue Letter to Shareholders

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Amarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Form 4 - Statement of changes in beneficial ownership of securities

AMRN Discussion

Your Recent History

Company

Business

Popular

Get The App